Regeneron Pharmaceuticals (REGN) revealed a profit for its third quarter that increased from the same period last year and beat the Street estimates.
The company's bottom line came in at $1.341 billion, or $11.54 per share. This compares with $1.008 billion, or $8.89 per share, in last year's third quarter.
Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $1.462 billion or $12.46 per share for the period.
Analysts on average had expected the company to earn $11.69 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 10.6% to $3.721 billion from $3.363 billion last year.
Regeneron Pharmaceuticals earnings at a glance (GAAP) :
-Earnings (Q3): $1.341 Bln. vs. $1.008 Bln. last year.-EPS (Q3): $11.54 vs. $8.89 last year.-Revenue (Q3): $3.721 Bln vs. $3.363 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.